At the time of writing, Viracta Therapeutics Inc [VIRX] stock is trading at $0.21, down -4.62%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VIRX shares have gain 32.94% over the last week, with a monthly amount glided 16.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Viracta Therapeutics Inc [NASDAQ: VIRX] stock has seen the most recent analyst activity on August 16, 2024, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $3 from $5. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on February 01, 2022, and set its price target to $10. On May 03, 2021, H.C. Wainwright initiated with a Buy rating and assigned a price target of $35 on the stock. SVB Leerink started tracking the stock assigning a Outperform rating and suggested a price target of $18 on April 26, 2021. Evercore ISI initiated its recommendation with a Outperform and recommended $45 as its price target on March 25, 2021.
For the past year, the stock price of Viracta Therapeutics Inc fluctuated between $0.13 and $1.31. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Viracta Therapeutics Inc [NASDAQ: VIRX] shares were valued at $0.21 at the most recent close of the market. An investor can expect a potential return of 3709.52% based on the average VIRX price forecast.
Analyzing the VIRX fundamentals
Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -63.97%, Pretax Profit Margin comes in at -58.66%, and Net Profit Margin reading is -58.66%. To continue investigating profitability, this company’s Return on Assets is posted at -1.97, Equity is -6.8 and Total Capital is 7.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.56.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1866 points at the first support level, and at 0.1604 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2389, and for the 2nd resistance point, it is at 0.2650.
Ratios To Look Out For
It is important to note that Viracta Therapeutics Inc [NASDAQ:VIRX] has a current ratio of 0.76. As well, the Quick Ratio is 0.76, while the Cash Ratio is 0.46.
Transactions by insiders
Recent insider trading involved Chevallard Daniel R., CFO and COO, that happened on Feb 27 ’24 when 3405.0 shares were sold.
